Rituximab therapy in pemphigus and other autoantibody-mediated diseases [version 1; referees: 3 approved]

Abstract

Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.

Keywords

• Acquired & Inherited Bullous Disorders
• Autoimmunity
• Bleeding & Coagulation Disorders
• Dermatologic Pathology
• Dermatologic Pharmacology
• Immunopharmacology & Hematologic Pharmacology
• Leukocyte Signaling & Gene Expression
• Medical Genetics
• Multiple Sclerosis & Related Disorders
• Musculoskeletal Pharmacology
• Neuromuscular Diseases
• Perioperative Hemostasis & Transfusion Medicine
• Urticaria, Vasculitis & Connective Tissue Disease